SEC Tracker
Get the app

Indivior Pharmaceuticals INDV

Indivior announces merger with Supernus

Form
8-K
Filed
Importance
Routine
  1. Merger to be completed on October 15, 2026
  2. Supernus to become subsidiary of Indivior
  3. Indivior to be renamed Supernus, Inc.
  4. Registration Statement effective September 11, 2026

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Indivior Pharmaceuticals files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Apellis Pharmaceuticals APLS public float $1.8B, Jun 30, 2025
  2. Biocryst Pharmaceuticals BCRX public float $1.9B, Jun 30, 2025
  3. Agios Pharmaceuticals AGIO public float $1.9B, Jun 30, 2025
  4. Amicus Therapeutics FOLD public float $1.7B, Jun 30, 2025
  5. Supernus Pharmaceuticals SUPN public float $1.7B, Jun 30, 2025